Safety and efficacy of Hemicell&#174; HT (endo&#8208;1,4&#8208;&#946;&#8208;d&#8208;mannanase) as a feed additive for chickens for fattening, chickens reared for laying, turkey for fattening, turkeys reared for breeding, weaned piglets, pigs for fattening and minor poultry and porcine species by G. Rychen et al.
SCIENTIFIC OPINION
ADOPTED: 7 December 2016
doi: 10.2903/j.efsa.2017.4677
Safety and efﬁcacy of Hemicell® HT (endo-1,4-b-D-
mannanase) as a feed additive for chickens for fattening,
chickens reared for laying, turkey for fattening, turkeys
reared for breeding, weaned piglets, pigs for fattening and
minor poultry and porcine species
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP),
Guido Rychen, Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos,
Georges Bories, Andrew Chesson, Gerhard Flachowsky, J€urgen Gropp, Boris Kolar,
Maryline Kouba, Marta Lopez Alonso, Secundino Lopez Puente, Alberto Mantovani,
Baltasar Mayo, Fernando Ramos, Maria Saarela, Roberto Edoardo Villa, Robert John Wallace,
Pieter Wester, Paul Brantom, No€el Albert Dierick, Boet Glandorf, Lieve Herman,
Sirpa K€arenlampi, Jaime Aguilera, Montserrat Anguita and Pier Sandro Cocconcelli
Abstract
Hemicell® HT is a feed additive with endo-1,4-b-D-mannanase as the main enzymatic activity that is
available in solid (HT) and liquid (HT-L) forms. The production strain of the enzyme is a genetically
modiﬁed strain of Paenibacillus lentus. The recipient strain is considered to be safe, the sequences
introduced to obtain the production strain do not raise safety concerns. The absence of the production
strain and of recombinant DNA in the product was not proven. The additive is safe for the target species
at the corresponding recommended doses. The use of Hemicell® HT as a feed additive does not give
rise to concerns for consumers. Hemicell® HT and Hemicell® HT-L are not irritant to the skin and eyes;
Hemicell® HT is a skin sensitiser. No speciﬁc data were provided on the effects on the respiratory
system; however, considering the nature of the active substance, the additive is considered a potential
respiratory sensitiser. The active substance of the additive is a protein, and as such, it will be degraded/
inactivated during passage through the digestive tract of the animals or in the environment. However,
uncertainty remains on the absence of the production strain and of recombinant DNA in the product,
consequently, the EFSA FEEDAP Panel could not conclude on the environmental safety of the product
with regard to the genetically modiﬁed production strain. The additive has the potential to be efﬁcacious
in chickens for fattening at 32,000 U/kg feed and at 48,000 U/kg feed in turkeys for fattening and
weaned piglets. These conclusions were extended to chickens reared for laying and turkeys reared for
breeding and extrapolated to minor poultry species for fattening or reared for laying/breeding. The
Panel could not conclude on the efﬁcacy of the product in pigs for fattening or in minor porcine species.
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Summary
Following a request from the European Commission (EC), the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Hemicell® HT (endo-1,4-b-D-mannanase) as a feed additive for chickens for fattening,
chickens reared for laying, turkeys for fattening, turkeys reared for breeding, weaned piglets, pigs for
fattening and minor poultry and porcine species.
The additive contains endo-1,4-b-D-mannanase (mannanase) which is produced by a genetically
modiﬁed strain of Paenibacillus lentus. The identity of the strain was conﬁrmed as P. lentus. The
recipient strain is considered to be safe, the sequences introduced to obtain the production strain do
not raise safety concerns. The absence of the production strain and of recombinant DNA in the
product was not proven.
Based on the tolerance trials evaluated, the FEEDAP Panel concluded that the additive is safe for
chickens for fattening at 32,000 U/kg and for turkeys for fattening and weaned piglets at 48,000 U/kg
feed. These conclusions were extended to chickens reared for laying and turkeys reared for breeding
and to pigs for fattening at the corresponding doses. Based on the wide margin of safety shown in the
major species, the conclusion was extrapolated to minor poultry species (for fattening or reared for
laying/breeding) and growing minor porcine species.
Based on the results obtained in the genotoxicity studies and in a subchronic oral toxicity study, the
Panel concluded that the use of Hemicell® HT as a feed additive is of no concern for consumers.
The FEEDAP Panel concluded that Hemicell® HT and Hemicell® HT-L are not irritant to the skin and
eyes; Hemicell® HT is a skin sensitiser. No speciﬁc data were provided on the effects on the
respiratory system; however, considering the nature of the active substance the additive was
considered a potential respiratory sensitiser.
The active substance of the additive is a protein, and as such it will be degraded/inactivated during
passage through the digestive tract of the animals or in the environment. However, since uncertainty
remains on the absence of the production strain and on the possible presence of recombinant DNA in
the product, the FEEDAP Panel could not conclude on the environmental safety of the product with
regard to the genetically modiﬁed production strain.
Based on the results of the studies done in chickens and turkeys for fattening and weaned piglets,
the FEEDAP Panel concluded that the additive has the potential to be efﬁcacious in chickens for
fattening at 32,000 U/kg feed and in turkeys for fattening and weaned piglets at 48,000 U/kg feed.
These conclusions were extended/extrapolated to chickens reared for laying and turkeys reared for
breeding at the corresponding doses. The conclusions reached in chickens for fattening were
extrapolated to minor poultry species for fattening or reared for laying/breeding. The Panel could not
conclude on the efﬁcacy of the product in pigs for fattening or in minor porcine species.
Hemicell® HT for poultry and pigs
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2017;15(1):4677
Table of contents
Abstract.................................................................................................................................................. 1
Summary................................................................................................................................................ 3
1. Introduction................................................................................................................................ 5
1.1. Background and Terms of Reference............................................................................................. 5
1.2. Additional information.................................................................................................................. 5
2. Data and methodologies .............................................................................................................. 5
2.1. Data........................................................................................................................................... 5
2.2. Methodologies............................................................................................................................. 5
3.1. Characterisation .......................................................................................................................... 6
3.1.1. Characterisation of the active substance ....................................................................................... 6
3.1.2. Manufacturing process................................................................................................................. 6
3.1.3. Characterisation of the additive .................................................................................................... 6
3.1.4. Shelf life, stability and homogeneity.............................................................................................. 7
3.1.4.1. Shelf life ..................................................................................................................................... 7
3.1.4.2. Stability and homogeneity of the additive in premixtures and feedingstuffs...................................... 7
3.1.5. Conditions of use ........................................................................................................................ 8
3.2. Safety ........................................................................................................................................ 8
3.2.1. Safety aspects of the genetic modiﬁcation..................................................................................... 8
3.2.2. Safety for the target species ........................................................................................................ 8
3.2.2.1. Safety for chickens for fattening ................................................................................................... 8
3.2.2.2. Safety for turkeys for fattening..................................................................................................... 9
3.2.2.3. Safety for weaned piglets ............................................................................................................ 9
3.2.2.4. Safety for pigs for fattening ......................................................................................................... 10
3.2.2.5. Conclusions on safety for the target species .................................................................................. 10
3.2.3. Safety for the consumer .............................................................................................................. 10
3.2.3.1. Genotoxicity................................................................................................................................ 10
3.2.3.2. Subchronic oral toxicity study ....................................................................................................... 11
3.2.3.3. Conclusions on the safety for the consumer .................................................................................. 11
3.2.4. Safety for the user ...................................................................................................................... 11
3.2.4.1. Effects on the respiratory system.................................................................................................. 11
3.2.4.2. Effects on the skin and eyes ........................................................................................................ 11
3.2.4.3. Conclusions on safety for the user ................................................................................................ 12
3.2.5. Safety for the environment .......................................................................................................... 12
3.3. Efﬁcacy ...................................................................................................................................... 12
3.3.1. Efﬁcacy for chickens for fattening ................................................................................................. 12
3.3.2. Efﬁcacy for turkeys for fattening................................................................................................... 14
3.3.3. Efﬁcacy for weaned piglets........................................................................................................... 15
3.3.3.1. Short-term trial ........................................................................................................................... 15
3.3.3.2. Long-term trials .......................................................................................................................... 15
3.3.4. Efﬁcacy for pigs for fattening ....................................................................................................... 17
3.3.4.1. Short-term trial ........................................................................................................................... 17
3.3.4.2. Long-term trials .......................................................................................................................... 17
3.3.5. Conclusions on the efﬁcacy .......................................................................................................... 19
3.4. Post-market monitoring................................................................................................................ 19
Documentation provided to EFSA ............................................................................................................. 20
References.............................................................................................................................................. 20
Abbreviations .......................................................................................................................................... 21
Annex A – Executive Summary of the Evaluation Report of the European Union Reference Laboratory for
Feed Additives on the Methods of Analysis for Hemicell® HT ...................................................................... 22
Hemicell® HT for poultry and pigs
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2017;15(1):4677
1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Eli Lilly and Company Ltd.2 for authorisation of
the product Hemicell® HT (endo-1,4-b-D-mannanase), when used as a feed additive for chickens for
fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, weaned
piglets, pigs for fattening and minor poultry/porcine species (category: zootechnical additive; functional
group: digestibility enhancers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of this application. The particulars and documents in support
of the application were considered valid by EFSA as of 17 April 2015.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Hemicell® HT (endo-1,4-b-D-mannanase), when used under the proposed conditions of use
(see Section 3.1.5).
1.2. Additional information
The additive under assessment is not currently authorised for use in food and feed in the European
Union (EU). It has not been previously assessed by EFSA as a feed additive.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier3 in support of the authorisation request for the use of Hemicell® HT as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20084 and the applicable EFSA guidance documents.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active substance in animal feed. The Executive Summary of the
EURL report can be found in Annex A.5
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Hemicell® HT
is in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a), Guidance for establishing
the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on studies concerning
the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c), Guidance on the
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Eli Lilly and Company Ltd. Eli Lilly Regional Operations Ges. m. b. H, Elanco Animal Health, Koelblgasse 8-10, A-1030, Vienna,
Austria.
3 FEED dossier reference: FAD-2014-0001.
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep-fad-2014-0001-hemicell.pdf
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assessment of bacterial susceptibility to antimicrobials of human and veterinary importance (EFSA
FEEDAP Panel, 2012d), Technical Guidance: Microbial Studies (EFSA, 2008b), Technical Guidance:
Extrapolation of data from major species to minor species regarding the assessment of additives for
use in animal nutrition (2008c) and Guidance on the risk assessment of genetically modiﬁed
microorganisms and their products intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
This assessment deals with the safety and efﬁcacy of Hemicell® HT as a zootechnical additive
(digestibility enhancer) for chickens for fattening, chickens reared for laying, turkeys for fattening,
turkeys reared for breeding, weaned piglets, pigs for fattening and minor poultry/porcine species.
3.1. Characterisation6
3.1.1. Characterisation of the active substance
The additive contains endo-1,4-b-D-mannanase (Enzyme Commission number: 3.2.1.78,
mannanase) as the main enzyme activity. The applicant claims that there are no other side activities.
This enzyme is produced by a genetically modiﬁed strain of Paenibacillus lentus (formerly named
Bacillus lentus), which is deposited at the German Collection of Microorganisms and Cell Cultures,
(DSMZ), with the accession number DSM 28088.7 The strain was shown not to be haemolytic,8 not
cytotoxic to VERO cells,9 and is negative in the boar sperm mobility test.10 Susceptibility to the
relevant antibiotics listed in the Guidance on the assessment of bacterial susceptibility to antimicrobials
of human and veterinary importance (EFSA FEEDAP Panel, 2012d) was shown for one of the
intermediate strains during the genetic modiﬁcation process.11 The technical dossier contains detailed
and sufﬁcient information on the parental and recipient strains, including aspects on the safety of the
strain lineage, the origin, modiﬁcation and function of the different genetic elements modiﬁed in the
production strain, the genetic modiﬁcation process and the genetic and phenotypic traits modiﬁed.
3.1.2. Manufacturing process
The enzyme is obtained by submerged fermentation. After fermentation, the resulting product,
liquid intermediate, is mixed with excipients for the preparation of the liquid formulation of the product
or spray-dried and then mixed with excipients/carriers (see Section 3.1.3) to prepare the ﬁnal solid
formulation.
The applicant declared that no antimicrobial compounds, such as antibiotics, were used in the
manufacturing process.
3.1.3. Characterisation of the additive
The additive is available in two forms, solid (Hemicell® HT) and liquid (Hemicell® HT-L).
The solid formulation, Hemicell® HT, ensures a minimum of 160 9 106 Units12 mannanase per kg
product. The study of the batch-to-batch variation in ﬁve batches showed a mean value of
241 9 106 U/kg ranging from 235 9 106 to 248 9 106 U/kg (coefﬁcient of variation (CV) of 2.3%).13
This formulation contains (w/w) linseed meal (58%), calcium carbonate (38%), mineral oil (1%;
E905A parafﬁn) and dried fermentation product (3%, spray-dried with maltodextrin). Particle size
distribution was measured in three lots by laser diffraction analysis14 and showed a mean particle size
between 239.8 and 260.7 lm, particles below 100 lm represented 13–18% (v/v), particles below
50 lm 5–9% (v/v) and particles below 10 lm represented 0.9–1.7% (v/v). The dusting potential was
6 This section has been amended following the conﬁdentiality claim made by the applicant.
7 Technical dossier/Section II/Annex II.2.1.2.2.
8 Technical dossier/Section II/Annex II.2.2.2.2.
9 Technical dossier/Section II/Annex II.2.2.2.3.1.
10 Technical dossier/Section II/Annex II.2.2.2.3.2.
11 Technical dossier/Section II/Annex II.2.2.2.1.
12 One unit is deﬁned as the amount of mannanase enzyme which generates 0.72 mg of reducing sugars per minute from a
mannan-containing substrate at pH 7.0 and 40°C.
13 Technical dossier/Section II/Annex II.1.3.5.
14 Technical dossier/Section II/II.1.5.2.
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measured in three batches using the Stauber–Heubach method and ranged from 0.03 to 0.04 g/m3.15
The bulk density of the formulation ranges from 0.753 to 0.801 g/cm3.16
The liquid formulation, Hemicell® HT-L, ensures a minimum of 590 9 106 Units mannanase per L
product. The study of the batch-to-batch variation in ﬁve batches showed a mean value of
853 9 106 U/L ranging from 799 9 106 to 876 9 106 U/L (CV of 3.6%).17 This formulation contains
(w/w) sorbitol (48.6% (70% solution in water)), liquid fermentation product (20%), sodium chloride
(8%), monosodium glutamate (4%), sodium acetate (0.7%), caramel colour (0.2%), potassium sorbate
(0.1%), calcium chloride (0.1%) and added water (18.3%). The viscosity of this formulation ranges
8.2–10.4 Cp (measured at 25°C) and the surface tension 62.6–71.7 dynes/cm (measured at 23°C).18
Three batches of each ﬁnal formulation were analysed for chemical and microbial contamination.19
Chemical contamination included the analysis of lead (< 0.53 mg/kg in the solid and < 0.05 mg/kg in
the liquid), cadmium (< 0.49 mg/kg in the solid and < 0.25 mg/kg in the liquid), mercury (< 0.1 mg/kg),
antimony (< 0.5 mg/kg), bismuth (< 1.0 mg/kg), copper (< 11 mg/kg in the solid and < 0.5 mg/kg in
the liquid), ﬂuorine (< 10.2 mg/kg in the solid and < 5 mg/kg in the liquid), molybdenum (0.53 mg/kg in
the solid and < 0.5 mg/kg in the liquid), silver (< 0.5 mg/kg), tin (< 2 mg/kg) and arsenic (0.50 mg/kg).
The following mycotoxins were analysed, aﬂatoxins (B1, B2, G1 and G2, < 1.1 lg/kg), zearalenone
(< 25 lg/kg), ochratoxin A (< 3.7 lg/kg), T2 toxin (< 25 lg/kg) fumonisins (< 1 mg/kg) and deoxynivalenol
(0.5 mg/kg). Dioxins and dioxin-like PCBs were also analysed (WHO-PCDD/F-TEQ, < 1.5 ng/kg). Microbial
contamination included the study of Salmonella spp. (absence in 25 g) in the two formulations and E. coli
(not detected in 25 g), coliform bacteria (not detected) and aerobic plate counts (< 1,900 colony-forming
units (CFU)/mL) in the liquid formulation.
The applicant investigated the presence of the production strain and its DNA in the intermediate
product that is used to formulate the additive. Owing to the methodologies followed uncertainty
remains on the presence of the production strain and its recombinant DNA in the additive.
Antimicrobial activity was found to be absent in the liquid culture supernatant and in the liquid
intermediate used to formulate the additive, three batches each, following the method speciﬁed by the
Joint FAO/WHO Expert Committee on Food Additives (FAO JECFA, 2006).20
3.1.4. Shelf life, stability and homogeneity
3.1.4.1. Shelf life
The shelf life of the solid formulation (three batches, mean enzyme activity 260 9 106 U/kg) was
tested in samples stored in closed polypropylene bags at 5, 25, 30 and 40°C for 15, 24, 24 or
18 months, respectively.21 After 15 months at 5°C, mean enzyme recovery was 87%. After 24 months
storage at 25 or 30°C, the mean enzyme recoveries were 65% and 53%, and after 18 months at
40°C, recovery was 25%.
Shelf life of the liquid formulation (three batches, mean enzyme activity 830 9 106 U/L) was tested
in samples stored in closed plastic bottles at 5, 25, 30 and 40°C up to 12 months.22 After 12 months,
samples stored at 5°C showed no modiﬁcations of the enzyme activity, samples stored at 25°C showed
recoveries of the enzyme activity between 60% and 100%, and those stored at 30°C showed recoveries
below 50%. After 9 months, samples kept at 40°C showed a complete loss of the enzyme activity.
3.1.4.2. Stability and homogeneity of the additive in premixtures and feedingstuffs
The stability of the solid formulation in complete vitamin–mineral premixtures for pigs was studied in
three batches of the additive. One batch was added to a vitamin–mineral premixture for pigs (without
choline chloride, supplemented at 59 9 106 U/kg) and the other two were added to a vitamin–mineral
premixture for laying hens (with choline chloride, supplemented at 50 9 106 U/kg). Samples were
stored in closed plastic bags at 25 or 30°C for 6 months or at 40°C for 2 months.23 Enzyme recovery
15 Technical dossier/Section II/Annex II.1.5.4.
16 Technical dossier/Section II/Annex II.1.5.3.
17 Technical dossier/Section II/Annex II.1.3.6.
18 Technical dossier/Section II/Annex II.1.5.5.
19 Technical dossier/Section II/Annex II.1.4.1.2.
20 Technical dossier/Section II/Annex II.1.4.1.3 and Supplementary information November 2015/Annex II.1.4.1.6 and
Supplementary information September 2016/Annex II.1.4.1.3.1.
21 Technical dossier/Supplementary information September 2016/Annex II.4.1.1.2.
22 Technical dossier/Section II/Annex II.4.1.2.
23 Technical dossier/Section II/Annex II.4.1.5.
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after 6 months storage at 25°C was 76% in the premixture for pigs and 34% in the layers’ premixtures.
The corresponding values for the samples stored at 30°C were 53% and 24%. After 2 months storage
at 40°C, recovery was of 100% in the premixture for pigs and of 37.5% in the premixture for layers.
The stability of Hemicell® HT and Hemicell® HT-L was studied in two complete feed for poultry and in
one feed for pigs in each formulation.24 The additive was added to the mash feed at an intended dose of
32,000 or 48,000 U/kg feed. Mash feed was pelleted at two different temperatures 70–75°C and 80–85°C.
Samples of mash and pelleted feed were stored at 25 and 30°C for 3 months or at 40°C for 2 months.
Recoveries of enzyme activity after heat treatment were ~ 90% of the initial activity for the two
formulations and the two temperatures tested. For the feed supplemented with the solid formulation,
recovery values after 3 months in samples stored at 25°C was 100% in the mash and 94% for the pelleted
samples. The corresponding values for samples kept at 30°C were 88% and 95%. After 2 months, the
recovery in samples kept at 40°C were 83% for mash and pelleted feeds. For the feed supplemented with
the liquid formulation, recovery values showed no enzyme activity losses in any of the conditions studied.
Ten subsamples of two of the premixtures and feeds used for the stability test were analysed in
order to study the capacity of the additive to homogeneously distribute. The CV was 15.8% in the
premixture for pigs and of 17% in the one for layers, in mash feed was of 12% and 7% for solid and
liquid form, respectively, and in pelleted feed it was of 7% and 6%, respectively.
3.1.5. Conditions of use
The additive is to be used in chickens for fattening, chickens reared for laying, pigs for fattening
and minor poultry or porcine species at a dose of 32,000 U/kg feed and in turkeys for fattening,
reared for laying or for breeding and weaned piglets at 48,000 U/kg feed.
3.2. Safety
3.2.1. Safety aspects of the genetic modiﬁcation6
The recipient organism is considered to be safe. Susceptibility to the antimicrobials listed in the
Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary
importance (EFSA FEEDAP Panel, 2012d) was demonstrated for an intermediate strain in the genetic
modiﬁcation process leading to the development of the production strain.11 The introduced sequences
raise no safety concern.
3.2.2. Safety for the target species
3.2.2.1. Safety for chickens for fattening
A total of 2,100 1-day-old male chickens (Ross 308) were penned in groups of 35 birds and
allocated to one of ﬁve dietary treatments (representing 12 replicates per treatment).25 Starter, grower
and ﬁnisher basal diets based on wheat and soya protein were either not supplemented (control) or
supplemented with the mannanase at 32,000 (19), 48,000, 64,000 or 7,000,000 (2189) U/kg feed.
The enzyme activity in the diets was conﬁrmed with the exception of the diet with the highest
supplementation level which showed recoveries similar to 65% of the intended dosage. Diets were
offered to the birds for 42 days on ad libitum basis in pelleted form. Diets contained monensin sodium
as a coccidiostat. Health status and mortality of the birds were monitored throughout the study. Feed
intake and body weight were recorded and feed to gain ratio was calculated. Blood samples were
collected from one bird per pen (12 birds per treatment) from the control group and animals from the
two highest doses, and analysed for haematological26 and biochemical parameters.27 The same birds
were subject to necropsy for gross pathology. An analysis of variance (ANOVA) was carried out with
the data and group means were compared with Tukey test. The pen was the experimental unit.
Mortality was low and no differences were found between treatments (2.6%, 3.6%, 2.9%, 2.9% and
3.1% in the ﬁve groups). Mean total feed intake of the birds during the study was ~ 5.0 kg, mean ﬁnal
body weight was ~ 3.2 kg and mean feed to gain ratio was ~ 1.79 and were not affected by the dietary
24 Technical dossier/Section II/Annex II.4.1.3 and II.4.1.4.
25 Technical dossier/Section III/Annex III.1.1.1.
26 Including: red blood cell counts, haemoglobin, packed cell volume, mean corpuscular volume, mean corpuscular haemoglobin
concentration, white blood cell counts including heterophil, lymphocyte, monocyte, eosinophil and basophil.
27 Including aspartate aminotransferase, creatinine, calcium, phosphate, magnesium, urea, alkaline phosphatase, cholesterol,
triglycerides and glucose.
Hemicell® HT for poultry and pigs
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2017;15(1):4677
treatments. No modiﬁcations were found on the haematological parameters studied. Biochemical
parameters showed increases in the 64,000 dose compared to the control in the urea (1.10, 1.33,
1.27 mmol/L for control, 64,000 and 7,000,000 U/kg, respectively), cholesterol (3.12, 3.58 and
3.26 mmol/L, respectively) and calcium (2.90, 3.07 and 3.01 mmol/L, respectively), however, these
differences were not present in the 7,000,000 group. Magnesium (1.23, 1.36, 1.42 mmol/L for 0, 64,000
and 7,000,000 U/kg) and phosphate (3.69, 4.09, 4.08 mmol/L) were higher in the supplemented groups
as compared to the control. However, these modiﬁcations are considered to be of no concern. Therefore,
the FEEDAP Panel considers that the additive is safe for chickens for fattening at the recommended dose.
3.2.2.2. Safety for turkeys for fattening
A total of 560 1-day-old male turkeys (Nicholas 85) were penned in groups of 10 birds and allocated
to four dietary treatments (14 pens per treatment).28 Starter and grower basal diets based on maize
and soya bean meal were supplemented with the mannanase to provide 0, 48,000 (19), 480,000 (109)
or 4,800,000 (1009) U/kg feed (conﬁrmed by analysis). Diets were offered to the birds for 84 days on
ad libitum basis and in pelleted form. The diets contained monensin sodium as a coccidiostat. Health
status of the birds was monitored throughout the study. Feed intake, body weight and mortality were
recorded and feed to gain ratio was calculated. Blood samples were collected from one bird per pen (14
per treatment) and analysed for haematological29 and biochemical30 parameters. An ANOVA was
performed with the data (pen basis), and mean groups were compared to the control with Dunnett test.
Mortality was low and no differences were found between treatments (2.1%, 3.6%, 2.1% and
4.3%). Mean daily feed intake during the study (g/bird) was ~ 225 g, average daily weight gain was
~ 115 g and feed to gain ratio was ~ 1.92 and were not affected by the dietary treatments.
Haematology and biochemical parameters results showed some statistical differences on the
parameters measured. In the 10-fold dose compared to the control, there was a lower haemoglobin
content (11.1, 10.7, 10.6 and 11.1 g/dL for control, 19, 109 and 1009, respectively) and a higher
triglyceride concentration (103, 103, 121 and 107 mg/dL), but these decreases were not found in the
100-fold dose. In the 100-fold dose, the uric acid concentration was higher compared to the control
diet (5.1, 4.9, 5.7, 6.3 mg/dL for control, 19, 109 and 1009, respectively). However, these changes
are considered to be of no concern. Therefore, the FEEDAP Panel considers that the additive is safe for
turkeys for fattening at the recommended dose.
3.2.2.3. Safety for weaned piglets
A total of 315 20-day-old weaned piglets (females and castrated males, commercial breed, initial
body weight 6.4 kg) were allocated to pens in groups of ﬁve animals (sex separated) and allocated to
three dietary treatments (representing 21 replicates per treatment).31 Three basal diets (prestarter,
starter and weaner) based on maize and soya bean meal were either not supplemented (control) or
supplemented with the mannanase at 48,000 (19) or 4,800,000 (1009) U/kg feed. The analysis of the
100-fold diet showed recoveries close to 70% of the intended dosage. Feed was offered to the piglets
for 42 days on ad libitum basis in pelleted form. Health condition of the animals and mortality were
monitored throughout the study. Piglets were weighed and feed intake was measured on days 14, 28
and 42 and feed to gain was calculated. On day 42, one pig per pen was randomly selected and blood
was collected and analysed for haematological32 and biochemical33 parameters. An ANOVA was
performed with the data (pen basis) and group means were compared with the least signiﬁcant
difference (LSD) test.
One piglet from the onefold diet and one from the 100-fold groups died. Three piglets were
removed from the study due to lameness; the three belonged to the 100-fold diet. Compared to the
28 Technical dossier/Section III/Annex III.1.1.2.
29 Including: haematocrit, haemoglobin, white blood cell counts (including differential) and thrombocytes.
30 Including: albumin, globulin (and ratio), chloride, cholesterol, glucose, potassium, sodium, total protein, triglycerides, uric
acid, gamma-glutamyl transpeptidase, alanine aminotransferase, aspartate transaminase, blood urea nitrogen, creatinine and
total bilirubin.
31 Technical dossier/Section III/Annex III.1.1.3 and Supplementary information November 2015/Annex III.1.1.3_amendment.
32 Including: red blood cells count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean
corpuscular haemoglobin concentration, red blood cell distribution width, white blood cells (including differential), platelet
concentration and mean platelet volume.
33 Including: creatinine, blood urea nitrogen, total bilirubin, sodium, potassium, chloride, total protein, albumin, globulin,
calcium, phosphorus, magnesium, cholesterol, glucose, alkaline phosphatase, aspartase aminotransferase, creatine kinase,
gamma-glutamyl transpeptidase, glutamate dehydrogenase, beta-hydroxytutyrate, non-esteriﬁed fatty acid, carbon dioxide,
ion-gap.
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control diet, the diets containing the mannanase had a signiﬁcantly higher ﬁnal body weight (24.4,
26.3 and 26.2 kg for control, 19 and 1009, respectively) and a signiﬁcantly higher daily feed intake
(681, 720 and 718 g/pig, respectively). The feed to gain ratio was signiﬁcantly improved with the diets
containing the mannanase as compared to the control (1.58, 1.51 and 1.51 for control, 19 and 1009,
respectively).34 Haematological parameters showed a decrease in the platelet concentration in the
supplemented diets (570.6, 417.1 and 441.8 K/lL for control, 19 and 1009, respectively). Compared
to the control diet, the onefold diet showed lower blood urea nitrogen values (10.1, 7.9 and 8.9 mg/dL
for control 19 and 1009, respectively) and cholesterol (94.6, 85.3 and 86.7 mg/dL) and higher
glucose concentrations (105, 114 and 108 mg/dL). In the 100-fold diet, alkaline phosphatase (255,
242 and 216 U/L) and gamma-glutamyl transpeptidase (32.6, 30.1 and 25.0 U/L) were lower
compared to control. A lower globulin (1.90 vs 1.60 and 1.61 g/dL) and higher albumin (2.86 vs 3.29
and 3.39 g/dL) were found in the supplemented groups compared to control. However, these changes
are considered to be of no concern. Therefore, the FEEDAP Panel considers that the additive is safe for
the weaned piglets at the recommended dose.
3.2.2.4. Safety for pigs for fattening
No speciﬁc study was provided to demonstrate the tolerance for pigs for fattening. The FEEDAP
Panel considers that the conclusions reached for piglets can be extended to pigs for fattening.
3.2.2.5. Conclusions on safety for the target species
Based on the studies provided in chickens and turkeys for fattening and in piglets, the FEEDAP
Panel concludes that the additive is safe at 32,000 U/kg feed for chickens for fattening and at
48,000 U/kg feed in turkeys for fattening and weaned piglets. These conclusions can be extended to
chickens reared for laying at 32,000 U/kg feed and to turkeys reared for breeding and pigs for
fattening at 48,000 U/kg feed. Considering the wide margin of safety shown in these studies, the
conclusions are extrapolated to minor poultry species (for fattening or raised for laying/breeding) and
to growing minor porcine species at 48,000 U/kg feed.
3.2.3. Safety for the consumer
3.2.3.1. Genotoxicity
Bacterial reverse mutation assay
The fermentation product that is used to prepare the additive was tested to evaluate its mutagenic
potential in Salmonella Typhimurium strains TA98, TA100, TA1535 and TA1537 and in E. coli strain
WP2 uvrA in the presence and absence of an exogenous metabolic activation system (Aroclor 1,254-
induced rat liver S9) up to a maximum concentration of 5,000 lg per plate, in compliance with the
Organisation for Economic Co-operation and Development (OECD) Guideline 471.35 Water was used as
the vehicle. Two independent experiments were performed. Neither precipitate nor toxicity was
observed. No positive mutagenic responses were observed with any of the tester strains in either the
presence or absence of metabolic activation, while the positive controls performed as expected.
In vitro mammalian cell micronucleus test
The fermentation product that is used to prepare the additive was tested to evaluate the potential
to induce micronuclei in Chinese hamster ovary (CHO) cells in both the absence and presence of an
exogenous metabolic activation system (Aroclor 1254-induced rat liver S9) in compliance with the
OECD Guideline 487.35 Water was used as the vehicle. Based on the results of a preliminary toxicity
assay, the concentrations selected for testing ranged from 0.2 to 2,000 lg/mL. Two treatment
schedules were applied: 4-h treatment followed by 20-h recovery in the presence of cytochalasine-B,
with and without metabolic activation; 24-h treatment in the presence of cytochalasine-B, only without
metabolic activation. Cytotoxicity (58% cytokinesis-blocked proliferation index) was observed only at
the top concentration only in the 24-h exposure group without metabolic activation.
No signiﬁcant or dose-dependent increases in micronuclei induction were observed in any group
treated with the test item, with or without S9 (p > 0.05; Fisher’s Exact and Cochran–Armitage tests),
while the positive controls induced signiﬁcant increases in the percentage of micronucleated cells.
34 Feed to gain ratio was calculated from the gain to feed ratio reported in the study report.
35 Technical dossier/Supplementary information September 2016/Annex III.2.2.2.1.1.
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3.2.3.2. Subchronic oral toxicity study
The systemic toxic potential of the fermentation product used to prepare the additive to rats by
oral administration was assessed over a period of 13 weeks, in compliance with OECD Guideline 408.36
The test was preceded by a dose-range ﬁnding study in which oral doses up to 1,000 mg/kg body
weight (bw) and day were well tolerated. Four groups of 10 Crl:CD® SD rats of each sex received the
test material by gavage (10 mL/kg bw per day) for 91 days at doses of 0, 250, 500 or 1,000 mg/kg
bw per day. The control group received the vehicle (distilled water). During the study, clinical
condition, body weight and food consumption were recorded. Detailed clinical observations were
conducted weekly and functional evaluations and ophthalmic examinations were conducted at the
beginning and at the end of the study. Blood samples were taken at the end of the study from all
animals for haematology37 and blood chemistry measurements.38 Urine samples were collected for
analysis. All animals were subject to a necropsy during which organ weights were recorded,39 gross
pathology observations were made and tissues samples preserved for histological examination. Slides
were prepared from tissues collected from control and high-dose groups and were examined
microscopically for histopathological changes.
There were no effects of treatment on mortality, clinical observations, ophthalmoscopy or functional
observations. During the study, the food intake and body weight of all groups was similar. High-dose
females had signiﬁcantly lower counts of reticulocytes and neutrophils compared with controls, but a
similar effect was not seen in males. High-dose males had a signiﬁcantly shorter mean prothrombin
time but this difference was not reproduced in females. Serum urea nitrogen was slightly higher than
controls in high-dose females. There were no differences in organ weights or histopathology which
could be attributed to treatment. This study did not identify any effects of treatment which would be
of concern.
A further subchronic oral toxicity study performed in compliance with the OECD Guideline 408 was
provided. The test item used in that study was derived from the parental strain of the current
production strain. The results showed no treatment-related effect. The Panel considers this study as
supporting evidence of the safety of the product.
3.2.3.3. Conclusions on the safety for the consumer
The results obtained with the fermentation product used to prepare the additive in the genotoxicity
studies and in the subchronic oral toxicity study do not indicate any reason for concern for consumer
safety arising from the use of the product as a feed additive.
3.2.4. Safety for the user
3.2.4.1. Effects on the respiratory system
No speciﬁc studies were submitted. Owing to the proteinaceous nature of the active substance, the
additive is considered a potential respiratory sensitiser. The solid formulation has particles below 10 lm
but the dusting potential is low, consequently, the potential exposure is expected to be limited.
3.2.4.2. Effects on the skin and eyes
The acute dermal irritant potential of Hemicell® HT and Hemicell® HT-L was investigated in rabbits
in compliance with the OECD Guideline 404.40 No dermal irritation was observed in any animal at any
time point during the study. The test materials were classiﬁed as not irritant to the skin.
The eye irritancy potential of Hemicell® HT and Hemicell® HT-L was investigated in accordance with
the OECD Guideline 405.41 No effects were seen 24 h post-dose and later. The test materials were
classiﬁed as not irritant to the eyes.
36 Technical dossier/Supplementary information November 2015/Annex III.2.2.5.
37 Including: haematocrit, haemoglobin, mean corpuscular volume, mean corpuscular haemoglobin, mean crorpuscular
haemoglobin content, red blood cells, leucocytes (including differential), platelets, prothrombin time, ﬁbrinogen,
thromboplastin partial time.
38 Including: sodium, potassium chloride, calcium, phosphorus, alkaline phosphatase, total bilirubin, alanine transaminase,
aspartate transaminase, urea nitrogen, creatinine, total protein, albumin, globulin, triglyceride, cholesterol and glucose.
39 Including the adrenals, brain, heart, kidney, liver, pituitary gland, prostate, spleen, thymus, thyroid/parathyroid, uterus,
epididymis, ovaries, testis.
40 Technical dossier/Section III/Annex III.3.1.2.1 and Annex III.3.1.2.4.
41 Technical dossier/Section III/Annex III.3.1.2.2 and Annex III.3.1.2.5.
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The potential of Hemicell® HT and Hemicell® HT-L to cause or elicit skin sensitisation reactions
(allergic contact dermatitis) was assessed via the murine local lymph node assay (MLLNA), in
compliance with the OECD Guideline 429.42 Hemicell® HT exhibited skin sensitisation potential but not
Hemicell® HT-L.
3.2.4.3. Conclusions on safety for the user
Hemicell® HT and Hemicell® HT-L are not irritant to the skin and eyes; Hemicell® HT is a skin
sensitiser. The additive is considered a potential respiratory sensitiser.
3.2.5. Safety for the environment
The active substance of the additive is a protein, and as such it will be degraded/inactivated during
passage through the digestive tract of the animals or in the environment. However, uncertainty
remains on the absence of the production strain and on the absence of recombinant DNA in the
product. If those were present, the product should be subjected to environmental risk assessment
according to the Guidance on the risk assessment of genetically modiﬁed microorganisms and their
products intended for food and feed use (EFSA GMO Panel, 2011). Therefore, the EFSA FEEDAP
Panel cannot conclude on the environmental safety of the product.
3.3. Efﬁcacy
3.3.1. Efﬁcacy for chickens for fattening
A total of four long-term trials were evaluated. The ﬁrst three studies were conducted in the same
place and followed a similar study design. The fourth, conducted in another trial site, is the tolerance
trial presented in Section 3.2.2.1. The details of the design of the four studies are shown in Table 1
and the results of the trials in Table 2. In the four trials, 1-day-old male birds were used and were
under study for 42 days. In all trials, the basal diets (starter, grower and ﬁnisher) were either not
supplemented (control) or supplemented with the mannanase contained in the additive at different
inclusion levels (solid form in trials 1–3 and liquid intermediate in trial 4). The enzyme activities in the
feed were analysed. The recommended dosage (32,000 U/kg feed) was included in trials 1, 3 and 4.
In trial 1, the study design considered two different energy contents of the diets, high (H: 12.8 MJ
metabolisable energy (ME)/kg feed) or low (L: 12.5 MJ ME/kg feed). General health status and
mortality were monitored throughout the studies. Feed intake and body weight were measured and
feed to gain ratio was calculated. In each study, an ANOVA was performed with the data (pen basis)
and group means were compared using the Student–Newman–Keuls (trial 1) or Tukey test (trials 2, 3
and 4). Differences were considered statistically signiﬁcant at a level of at least p < 0.05.
The mortality was within the normal levels and no differences between the groups were identiﬁed.
The supplementation with mannanase improved the feed to gain ratio in three trials (1, 2 and 3) from
the nominal dose of 16,000 U/kg feed in trials 1 and 3 and from 22,400 U/kg feed in trial 2. The
supplementation of mannanase increased the body weight gain in one trial (trial 3) from the nominal
dose of 16,000 U/kg feed. The analysis of the diets showed that in general the enzyme activity in the
supplemented diets supplemented were higher than the intended. In the groups with the lowest
enzyme activity showing signiﬁcant effects, the analysed enzyme activity was 25,800, 31,000 and
14,600 U/kg feed. Therefore, the Panel considers that the additive has a potential to be efﬁcacious in
chickens for fattening at the recommended dose (32,000 U/kg feed).
42 Technical dossier/Section III/Annex III.3.1.2.3 and Annex III.3.1.2.6.
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Table 1: Trial design and dosages of the efﬁcacy trials performed in chickens for fattening
Trial
Breed
Gender
Duration
Total no. of animals
(animals/replicate)
Replicates/treatment
Basal diets
composition
(feed form)
Enzyme activity
(U/kg feed)
Intended Analysed
1(a) Cobb 9 Cobb
Males
42 days
2,800
(50)
8
Maize, soya bean
meal (pelleted)
0 (H)
32,000 (H)
0 (L)
16,000 (L)
32,000 (L)
48,000 (L)
64,000 (L)
2,433
43,533
4,066
29,866
38,533
56,100
77,800
2(b) Cobb 9 Cobb
Males
42 days
1,050
(50)
7
Maize, soya bean
meal (pelleted)
0
22,400
48,000
3,700
34,666
60,133
3(c) Cobb 9 Cobb
Males
42 days
1,600
(50)
8
Maize, soya bean
meal (pelleted)
0
16,000
32,000
48,000
8,766
23,433
39,333
52,033
4(d) Ross 308
Males
42 days
2,100
(35)
12
Wheat, soya
protein (pelleted)
0
32,000
48,000
64,000
7,000,000
24,333
69,466
71,900
82,700
6,487,200
(a): Technical dossier/Section IV/Annex IV.3.1.
(b): Technical dossier/Section IV/Annex IV.3.2 and Supplementary information November 2015.
(c): Technical dossier/Section IV/Annex IV.3.3 and Supplementary information November 2015/Annex IV.3.3.
(d): Technical dossier/Section IV/Annex III.1.1.
Table 2: Effects of Hemicell HT on the performance of chickens for fattening
Trial Treatment
Feed
intake(1)
Body weight
gain (g)
Feed to
gain ratio
Mortality
(%)
1 0 (H) 188 2,183a 1.82a 6.5
32,000 (H) 193 2,297a 1.78a 7.7
0 (L) 190 2,030c 1.93b 5.0
16,000 (L) 186 2,130bc 1.82a 5.5
32,000 (L) 188 2,158abc 1.81a 6.5
48,000 (L) 185 2,160abc 1.82a 8.5
64,000 (L) 183 2,145bc 1.80a 8.0
2 0 170 1,760 1.99a 7.7
22,400 170 1,800 1.93b 7.1
48,000 168 1,799 1.91b 6.9
3 0 192b 2,135b 1.85a 5.5
16,000 202a 2,311a 1.75b 2.7
32,000 199ab 2,294a 1.75b 3.0
48,000 194ab 2,283a 1.74b 4.5
4 0 5,686 3,167 1.79 2.6
32,000 5,722 3,210 1.78 3.6
48,000 5,830 3,232 1.80 2.9
64,000 5,652 3,180 1.78 2.9
7,000,000 5,673 3,190 1.78 3.1
(1): Values in trial 1, 2 and 3 are feed intake per pen in kilogram, in trial 4 are total feed intake per bird in gram.
a,b,c: Values within one column and within one trial with different superscripts are signiﬁcantly different (p < 0.05).
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3.3.2. Efﬁcacy for turkeys for fattening
A total of four long-term trials were evaluated; trial number 3 is the tolerance trial presented in
Section 3.2.2.2. The details of the design of the four studies are shown in Table 3 and the results of
the trials in Table 4. In all trials, 1-day-old birds were used and were under study for 84 days. The
basal diets (different number of diets according to the nutritional requirements of birds) were either
not supplemented (control) or supplemented with the additive (liquid form in trial 1 and solid in the
other trials) at different dosages. The recommended dose of 48,000 U/kg feed was considered in all
trials. The enzyme activities were analysed in all trials. General health status and mortality were
monitored throughout the studies. Feed intake and body weight were measured and feed to gain ratio
was calculated. In each study, an ANOVA was performed with the data (pen basis) and group means
were compared using the Tukey test (trials 1 and 4) or Dunnett (trials 2 and 3). Differences were
considered statistically signiﬁcant at a level of at least p < 0.05.
Mortality was low and no signiﬁcant differences between groups were identiﬁed. The
supplementation of the diets with the mannanase improved the feed to gain ratio in two trials (trials 1
and 3) at 48,000 U/kg feed and in another trial (trial 4) improved the body weight gain and feed to
gain ratio from the dose of 32,000 U/kg feed. Therefore, the Panel considers that the additive has a
potential to be efﬁcacious for turkeys for fattening at the recommended dose (48,000 U/kg feed).
Table 3: Trial design and dosages of the efﬁcacy trials performed in turkeys for fattening
Trial
Breed
Gender
Duration
Total no. of animals
(animals/replicate)
Replicates/treatment
Basal diets
composition
(feed form)
Enzyme activity
(U/kg feed)
Intended Analysed
1(a) BUT Big 6
females
84 days
540
(12)
15
Maize, soya bean meal
(pelleted)
0
32,000
48,000
3,850
34,875
49,950
2(b) Nicholas 85
females
84 days
420
(15)
14
Maize, soya bean meal
(pelleted)
0
48,000
6,000
62,250
3(c) Nicholas 85
Males
84 days
560
(10)
14
Maize, soya bean meal
(pelleted)
0
48,000
480,000
4,800,000
7,875
48,475
417,175
3,931,600
4(d) BUT Big 6
females
84 days
600
(10)
20
Wheat, barley, soya bean
meal (pelleted)
0
32,000
48,000
402
38,550
58,125
(a): Technical dossier/Section IV/Annex IV.3.4.
(b): Technical dossier/Section IV/Annex IV.3.5.
(c): Technical dossier/Section IV/Annex III.1.1.2.
(d): Technical dossier/Supplementary information November 2015/Annex IV.3.10.
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3.3.3. Efﬁcacy for weaned piglets
One short-term trial and four long-term trials were submitted by the applicant.
3.3.3.1. Short-term trial
A total of 72 43-day-old castrated male piglets (body weight 10.8 kg, (Large
White 9 Landrace) 9 Duroc) were individually penned and distributed to three dietary treatments.43 A
basal diet based on maize, soya bean meal and maize dried distillers grain solubles was either not
supplemented (control) or supplemented with the mannanase to provide 32,000 or 48,000 U/kg feed
(analysed values: 9,700, 52,100 and 75,700 U/kg). Piglets were fed the experimental diets on ad libitum
basis for 7 days. After this adaptation period, a total of 48 piglets were transferred to metabolic cages,
representing 16 replicates per treatment. The piglets were kept in the metabolic cages for 7 days and
fed the corresponding diets (amount equal to 9% of the metabolic body weight in two equal daily
portions). Body weight of the piglets was measured on days 0, 7 and 14, feed intake was measured.
Total collection of faeces and urine was carried out on the last four days of study. Total weight, dry
matter content, total nitrogen and energy content were determined in feed, faeces and urine. The ME
content of the diets was determined. An ANOVA was performed with the data and group means were
compared with Tukey test. Differences were considered statistically signiﬁcant at a level of at least p < 0.05.
No animals died or were removed from the study. The content of ME of the diets was signiﬁcantly
improved by Hemicell® HT addition only at the nominal dose of 32,000 U/kg feed (analytical value
42,000 U/kg feed) from 13.6 to 14.2 MJ/kg feed.
3.3.3.2. Long-term trials
A total of four long-term trials were evaluated. Trial number 2 is the tolerance trial presented in
Section 3.2.2.3. The details of the design of the four studies are shown in Table 5 and the results of
the trials in Table 6. In all trials, the basal diets (different number of diets according to the nutritional
requirements of the pigs) were either not supplemented (control) or supplemented with the additive
(liquid form in trial 1 and solid in the other trials) at different dosages. The recommended dose of
48,000 U/kg feed was considered in all trials. The enzyme activities were analysed in all trials. General
health status and mortality were monitored throughout the studies. Feed intake and body weight were
measured and feed to gain ratio or gain to feed were calculated. In each study, an ANOVA was
performed with the data (pen basis) and group means were compared using the Tukey test (trials 1
and 2) or Dunnett (trials 3 and 4). Differences were considered statistically signiﬁcant at a level of at
least p < 0.05.
The results of the single studies showed a signiﬁcant effect of the treatment in only one trial (trial
2). The data on daily feed intake, daily weight gain and the gain to feed ratio from the four studies
Table 4: Effects of Hemicell HT on the performance of turkeys for fattening
Trial Treatment
Daily feed
intake (g)
Body weight
gain (g)1
Feed to
gain ratio
Mortality
(%)
1 0 210 8,258 2.15a 1.7
32,000 210 8,417 2.11a 1.1
48,000 206 8,342 2.09b 1.7
2 0 199a 95 2.09a 2.2
48,000 196b 95 2.05b 3.1
3 0 224 117 1.91 2.1
48,000 222 115 1.92 3.6
480,000 224 116 1.92 2.1
4,800,000 224 115 1.94 4.1
4 0 204 95b 2.16a 0
32,000 202 98a 2.07b 1.0
48,000 206 99a 2.07b 1.0
(1): Values in trial 1 are total body weight gain and in trials 2–4 are individual body weight gain per day.
a,b,c: Values within one column and within one trial with different superscripts are signiﬁcantly different (p < 0.05).
43 Technical dossier/Section IV/Annex IV.2.1 and Supplementary information November 2015/Annex IV.2.1.
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were pooled and statistically analysed.44 The treatments included were the control and the
recommended dose (48,000 U/kg feed). The statistical model considered the effect of the treatment
and the study as main effects as well as their interaction. The results showed no signiﬁcance of the
interaction in any of the parameters evaluated. Hemicell® HT at 48,000 U/kg feed signiﬁcantly
improved the gain to feed ratio as compared to the control (1.65 vs 1.61, p = 0.03).45 No other
signiﬁcant effects were found.
The FEEDAP Panel concludes that the additive has a potential to be efﬁcacious in weaned piglets at
the recommended dose (48,000 U/kg feed).
Table 5: Trial design and dosages of the efﬁcacy trials performed in weaned piglets
Trial
Breed
Gender(e)
Duration
Total no. of animals
(animals/replicate)
Replicates/treatment
Basal diets
composition
(feed form)
Enzyme activity
(U/kg feed)
Intended Analysed
1(a) Large White 9 Landrace
♂
42 days
96
(4)
8
Wheat, barley, soya bean
(pelleted)
0
32,000
48,000
16,100
49,600
65,400
2(b) Commercial breed
♂ castrated/♀
42 days
315
(5)
21
Maize, soya bean meal
(pelleted)
0
48,000
4,800,000
8,000
36,000
3,460,000
3(c) Commercial breed
♂ castrated
42 days
390
(10)
13
Maize, soya bean meal
(pelleted/mash)
0
32,000
48,000
10,800
44,500
56,600
4(d) Commercial breed
♂/♀
42 days
120
(4)
10
Maize, barley, soya bean
meal (pelleted)
0
32,000
48,000
11,500
58,150
66,600
(a): Technical dossier/Section IV/Annex IV.3.6.
(b): Technical dossier/Section IV/Annex III.1.1.3 and Supplementary information November 2015/Annex III.1.1.3.
(c): Technical dossier/Supplementary information November 2015/Annex IV.3.11.
(d): Technical dossier/Supplementary information November 2015/Annex IV.3.12.
(e): In trial 2 – sex separated; in trial 4 – randomly distributed to treatments.
Table 6: Effects of Hemicell® HT on the performance of weaned piglets
Trial Treatment
Feed intake
(kg)(1)
Initial body
weight (kg)
Final body weight
gain (kg)
Feed to gain
ratio(2)
Mortality
(%)
1 0 53.9 9.7 36.4 2.02 0
32,000 54.2 9.8 36.6 2.02 0
48,000 55.1 9.6 37.0 2.01 0
2 0 0.681b 6.4 24.4b 1.58b 0
48,000 0.720a 6.4 26.3a 1.51a 1
4,800,000 0.718a 6.4 26.2a 1.52ab 4
3 0 0.805 7.7 31.2 1.43 3
32,000 0.816 7.7 31.5 1.44 1.5
48,000 0.788 7.7 30.8 1.43 3
4 0 0.828 6.7 25.0 1.89 0
32,000 0.878 6.7 26.6 1.84 0
48,000 0.819 6.7 25.4 1.84 3
(1): Values in trial 1 are total feed intake per pig and in trials 2–4 are individual daily feed intake.
(2): Values in trials 2–4 were calculated from the gain to feed reported in the studies.
a,b: Values within one column and within one trial with different superscripts are signiﬁcantly different (p < 0.05).
44 Technical dossier/Supplementary information November 2015/Annex IV.3.13.
45 Values calculated from the gain to feed reported in the study.
Hemicell® HT for poultry and pigs
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2017;15(1):4677
3.3.4. Efﬁcacy for pigs for fattening
One short-term trial and six long-term trials were submitted by the applicant.
3.3.4.1. Short-term trial
A total of 72 castrated male pigs (body weight 45 kg, (Large White 9 Landrace) 9 Duroc)) were
penned in groups of six animals and distributed to three dietary treatments. A basal diet based on
maize, wheat middlings, soybean hulls and soya bean meal was either not supplemented (control) or
supplemented with Hemicell® HT to provide 0, 32,000 or 48,000 U/kg feed (conﬁrmed by analysis:
2,205, 40,022 and 54,300 U/kg). Pigs were fed the experimental diets on ad libitum basis for 14 days.
After this adaptation period, a total of 60 pigs were randomly selected and transferred to metabolic
cages, representing 20 replicates per treatment. The pigs were kept in the metabolic cages for 7 days
and fed the corresponding diets (amount equal to 9% of the metabolic body weight in two equal daily
portions). Body weight of the pigs was measured on days 0, 14 and 21 and feed intake was measured
for these 14 days. Total collection of faeces and urine was carried out on the last four days of study.
Total weight, dry matter content, total nitrogen and energy content were determined in feed, faeces
and urine. The ME content of the diets was determined. An ANOVA was performed with the data and
group means were compared with a LSD test.
No animals died or were removed from the trial. The ME content in the diets was not affected by
the treatment (mean value 13.8 MJ/kg feed, p = 0.78).
3.3.4.2. Long-term trials
A total of six long-term trials were evaluated. The details of the design of the four studies are
shown in Table 7 and the results of the trials in Table 8. In all trials, the basal diets (different number
of diets according to the nutritional requirements of the pigs) were either not supplemented (control)
or supplemented with the additive (solid form) at different dosages. The recommended dose of
32,000 U/kg feed was considered in all trials. The enzyme activities were analysed in all trials. General
health status and mortality were monitored throughout the studies. Feed intake and body weight were
measured (at different time points, see Table 7) and feed to gain ratio or gain to feed were calculated.
In each study, an ANOVA was performed with the data (pen basis) and group means were compared
using the Tukey test (trials 1, 2 and 6), LSD (trial 3) or Dunett (trials 4 and 5). Differences were
considered statistically signiﬁcant at a level of at least p < 0.05.
The results of the single studies showed a signiﬁcant effect of the treatment in only one trial (trial
2, daily weight gain).
The data on daily feed intake, daily weight gain and the gain to feed ratio from four studies (2, 4, 5
and 6) were pooled by the applicant and statistically analysed.46 The analysis was done on the
average weight gain, daily feed intake and gain to feed ratio measured on days 82–84 (days under
study). The data considered included the control and the recommended dose (32,000 U/kg feed). The
statistical model considered the effect of the treatment and the study as main effects as well as their
interaction. The results showed no signiﬁcance of the interaction in any of the parameters evaluated.
Hemicell® HT at 32,000 U/kg feed signiﬁcantly improved the gain to feed ratio as compared to the
control (2.52 vs 2.48, p = 0.009).45 No other signiﬁcant effects were found.
The applicant was requested to pool the data from the six studies available. This request was not
followed. The applicant explained that trials 1 and 3 were not considered because the parameters
were not measured on day 82 of study; closest day in trial 1 was day 92 and in trial 3 day 77. The
FEEDAP Panel considers this exclusion as a weak point in the statistical approach. The data from the
six trials could be pooled and consideration of the different duration be done in the statistical analysis.
Therefore, the Panel is not in the position to accept such approach and considers that no conclusion
can be drawn from the data provided by the applicant.
46 Technical dossier/Supplementary information November 2015/Annex IV.3.17 and Supplementary information September 2016.
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Table 7: Trial design and dosages of the efﬁcacy trials performed in pigs for fattening
Trial
Breed
Gender(g)
Duration
(day controls)
Total no. of animals
(animals/replicate)
Replicates/treatment
Basal diets
composition
(feed form)
Enzyme activity
(U/kg feed)
Intended Analysed
1(a) Commercial breed
♂/♀
92 days
(0, 42, 92)
432
(12)
12
Barley, soya bean and
sunﬂower meal (pelleted)
0
32,000
48,000
8,800
34,600
46,200
2(b) Commercial breed
♂ castrated
106 days
(0, 28, 57, 82, 106)
300
(5)
20
Maize, soya bean meal
(pelleted)
0
32,000
48,000
8,800
35,000
46,000
3(c) Commercial breed
♂ castrated/♀
104 days
(0, 28, 56, 77, 104)(h)
309
(4–5)
21
Maize, soya bean meal
(mash)
0
32,000
48,000
4,200
37,400
49,300
4(d) Commercial breed
♂ castrated
84 days
(0, 21, 42, 70, 84)
380
(4–5)
26
Maize, soya bean meal
(mash)
0
32,000
48,000
8,500
46,800
77,000
5(e) Commercial breed
♂ castrated/females
82–84 days
(0, 28, 55, 77, 84)
60
(1)
20
Wheat, barley, maize,
soya bean meal (pelleted/
mash)
0
32,000
48,000
7,200
45,000
49,600
6(f) Pietrain
♂
83 days
(0, 37, 64, 83)
50
(1)
25
Wheat, barley, rye, soya
bean meal (pelleted)
0
32,000
12,700
55,000
(a): Technical dossier/Section IV/Annex IV.3.7 and Supplementary information November 2015/Annex IV.3.7.
(b): Technical dossier/Section IV/Annex IV.3.8 and Supplementary information November 2015/Annex IV.3.8.
(c): Technical dossier/Section IV/Annex IV.3.9.
(d): Technical dossier/Supplementary information November 2015/Annex IV.3.14.
(e): Technical dossier/Supplementary information November 2015/Annex IV.3.15.
(f): Technical dossier/Supplementary information November 2015/Annex IV.3.16.
(g): In trial 1 and 3, animals were sex separated.
(h): According to Supplementary information September 2016, measurements were done on days 0, 28, 56 and 98.
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3.3.5. Conclusions on the efﬁcacy
Based on the results of the efﬁcacy trials evaluated, the Panel concludes that the additive has a
potential to be efﬁcacious in chickens for fattening at 32,000 U/kg feed and at 48,000 U/kg feed in
turkeys for fattening and weaned piglets. The Panel considers that these conclusions can be extended
to chickens reared for laying and turkeys reared for breeding at the corresponding doses. The
conclusions reached in chickens for fattening can be extrapolated to minor poultry species for fattening
or reared for laying/breeding.
The Panel cannot conclude on the efﬁcacy of the product in pigs for fattening or in growing minor
porcine species.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation47 and Good
Manufacturing Practice.
4. Conclusions
The recipient strain is considered to be safe, the sequences introduced to obtain the production
strain do not raise safety concerns and there are no antibiotic resistance genes from the genetic
modiﬁcation in the production strain. The absence of the production strain and of recombinant DNA in
the product has not been proven.
The additive is safe for chickens for fattening at 32,000 U/kg feed and in turkeys for fattening and
weaned piglets at 48,000 U/kg feed. These conclusions can be extended to chickens reared for laying
and turkeys reared for breeding and to pigs for fattening at the corresponding doses. Based on the wide
margin of safety shown in the major species, the conclusion can be extrapolated to minor poultry species
(for fattening or reared for laying/breeding) and growing minor porcine species at 48,000 U/kg feed.
The use of Hemicell® HT as a feed additive does not give rise to concerns for consumers.
Table 8: Effect of Hemicell HT on the performance of pigs for fattening
Trial Treatment
Daily feed intake
(kg)
Body weight
(kg)(1) Daily weight gain
(kg)
Feed to
gain(2)
Mortality
(%)
Initial Final
1 0 1.52 22.9 87.1 0.699 2.17 3.4
32,000 1.54 22.9 89.3 0.722 2.14 2.0
48,000 1.54 22.9 88.9 0.719 2.14 0.7
2 0 2.61 27.5 129.0 0.967a 2.70 2.0
32,000 2.64 27.4 132.0 0.994b 2.65 2.0
48,000 2.63 27.5 131.9 0.989ab 2.66 2.0
3 0 2.69 25.7 129.1 0.993 2.71 1.9
32,000 2.72 25.7 129.5 0.995 2.73 1.9
48,000 2.69 25.8 130.8 1.00 2.68 4.9
4 0 2.61 31.1 119.1 1.05 2.48 2.3
32,000 2.60 31.4 119.9 1.06 2.46 0.8
48,000 2.64 31.9 120.9 1.06 2.48 0.8
5 0 2.63 22.7 103.5 0.975 2.70 0
32,000 2.60 22.7 103.6 0.975 2.67 0
48,000 2.61 22.7 102.4 0.961 2.72 0
6 0 2.63 25.6 113.7 1.06 2.47 0
32,000 2.64 25.5 115.8 1.09 2.42 0
(1): Values in trial 2 were calculated from the reported weight per pen.
(2): Values in trials 4 and 6 were calculated from the gain to feed reported in the studies.
a,b: Values within one column and within one trial with different superscripts are signiﬁcantly different (p < 0.05).
47 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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Hemicell® HT and Hemicell® HT-L are not irritant to the skin and eyes; Hemicell® HT is a skin
sensitiser. No speciﬁc data were provided on the effects on the respiratory system; however,
considering the nature of the active substance the additive is considered a potential respiratory
sensitiser.
The active substance of the additive is a protein, and as such it will be degraded/inactivated during
passage through the digestive tract of the animals or in the environment. However, since uncertainty
remains on the absence of the production strain and on the absence of recombinant DNA in the
product, the Panel cannot conclude on the environmental safety of the product.
The additive has a potential to be efﬁcacious in chickens for fattening at 32,000 U/kg feed and at
48,000 U/kg feed in turkeys for fattening and weaned piglets. These conclusions can be extended to
chickens reared for laying and turkeys reared for breeding at the corresponding doses. The
conclusions reached in chickens for fattening can be extrapolated to minor poultry species for fattening
or reared for laying/breeding. The Panel cannot conclude on the efﬁcacy of the product in pigs for
fattening or in minor porcine species.
Documentation provided to EFSA
1) Hemicell® HT for poultry and pigs. January 2014. Submitted by Eli Lilly and Company Ltd.
2) Hemicell® HT for poultry and pigs. Supplementary information. November 2015. Submitted
by Eli Lilly and Company Ltd.
3) Hemicell® HT for poultry and pigs. Supplementary information. September 2016. Submitted
by Eli Lilly and Company Ltd.
4) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for Hemicell® HT.
5) Comments from the Member States.
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Abbreviations
ANOVA analysis of variance
ATCC American Type Culture Collection
bw body weight
CFU colony-forming unit
CHO Chinese hamster ovary
CV coefﬁcient of variation
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen
EC European Commission
EURL European Union Reference Laboratory
FEEDAP Panel EFSA Panel on Additives and Products or Substances used in Animal Feed
LSD least signiﬁcant difference
ME metabolisable Energy
MLLNA murine local lymph node assay
OECD Organisation for Economic Co-operation and Development
PCR polymerase chain reaction
xgl xyloglucanase gene
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Hemicell® HT
In the current application authorisation is sought under article 4(1) for endo-1,4-b-mannanase
(EC 3.2.1.78), under the category/functional group 4(a) ‘zootechnical additives/digestibility enhancers’,
according to the classiﬁcation system of Annex I of Regulation (EC) No 1831/2003. The feed additive
is already authorised under the Commission Regulation (EC) No 786/2007 for chickens for fattening
and Commission Implementing Regulation (EU) No 103/2013. According to the Applicant, the feed
additive contains the active substance endo- 1,4-b-mannanase (EC 3.2.1.78) produced by the
Paenibacillus lentus strain.
The feed additive is intended to be marketed as solid (Hemicell® HT) or liquid (Hemicell® HT-L)
enzyme preparations, containing a minimum endo-1,4-b-mannanase activity of 1.6 9 108 U/kg and
5.9 9 108 U/L, respectively. According to the Applicant, the activity of endo-1,4-b-mannanase is
expressed in units (U), where 1 U is the amount of endo- 1,4-b-mannanase enzyme which liberates
0.72 micrograms of reducing sugars (mannose equivalents) per minute from mannan-containing
substrate (locust bean gum) at pH 7.0 and 40°C. Speciﬁcally, authorisation is sought for the use of
Hemicell®HT and Hemicell® HT-L for a variety of chickens, turkeys and pig species. The feed additive
is intended to be used directly into feedingstuffs or through premixtures (Hemicell® HT only) at a
recommended minimum endo-1,4-b-mannanase activity of 32,000 U/kg complete feedingstuffs.
For the quantiﬁcation of the endo-1,4-b-mannanase activity in the feed additive and feedingstuffs,
the Applicant submitted two single-laboratory validated and further veriﬁed colorimetric methods,
based on the reaction of reducing sugars (mannose equivalent) released by the action of endo-1,4-b-
mannanase on a mannan-containing substrate (locust bean gum, LBG) in the presence of 3,5-
dinitrosalicylic acid (DNS).
The following performance characteristics of the methods were reported in the frame of validation
and veriﬁcation studies for endo-1,4-b-mannanase activity in the feed additive and feedingstuffs
ranging from 245 to 690 and 0.015 to 10 mega (9106) units (MU)/kg, respectively: - a relative
standard deviation for repeatability (RSDr) ranging from 0.7% to 12.4%; - a relative standard
deviation for intermediate precision (RSDip) ranging from 4.2% to 12.4%; and - a recovery rate
(RRec) ranging from 91% to 126%. Furthermore, the Applicant reported the limit of quantiﬁcation
(LOQ) of 15,000 U/kg feedingstuffs, which is below the minimum activity recommended by the
Applicant in the conditions of use.
For the quantiﬁcation of endo-1,4-b-mannanase activity in premixtures the Applicant diluted
premixture samples with blank feed and applied the above mentioned method for feedingstuffs. Two
vitamin/mineral premixtures for poultry and swine were analysed in the frame of homogeneity studies
and a relative standard deviation for repeatability (RSDr) ranging from 15.8% to 17.2% was reported
for endo-1,4-b-mannanase activity ranging from 50 to 59 MU/kg premixtures.
Based on the performance characteristics presented, the EURL recommends for ofﬁcial control the
single-laboratory validated and further veriﬁed colorimetric methods, based on the enzymatic
hydrolysis and the reaction of reducing sugars (mannose equivalent) with 3,5- dinitrosalicylic acid
(DNS), for the quantiﬁcation of total endo-1,4-b-mannanase activity in the feed additive, premixtures
and feedingstuffs.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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